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Abstract 
This theme issue provides an overview on the biology and pathology of various integrins as 
well as in-depth discussion on the use of integrin as targeting molecules for molecular imaging 
and molecular therapy. 
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Integrins  are  a  family  of  heaterodimeric  trans-
membrane receptors each consisting of an α and a β 
subunit. A total of 18 α and 8 β subunits are known in 
mammalian cells, forming at least 24 different integrin 
receptors. Each integrin subunit contains a large ex-
tracellular domain, a single transmembrane domain 
and a short cytoplasmic domain. The composition and 
morphology  of  integrin-dependent  adhesions  vary 
with the cell type, matrix and integrin, contributing to 
cell  advancement,  tissue  remodeling  and  repair. 
Based  on  the  key  roles  they  play  in  angiogenesis, 
leukocytes function and tumor development and easy 
accessibility as cell surface receptors interacting with 
extracellular ligands, the integrin superfamily, integ-
rin αvβ3 in particular, have been extensively investi-
gated  as  imaging  and  therapy  targets.  This  theme 
collection of articles first introduces integrin biology 
followed  by  integrin  targeted  imaging  and  therapy 
applications.  Almost  every  imaging  modality,  in-
cluding positron emission tomography (PET), single 
photon  emission  computed  tomography  (SPECT), 
optical, magnetic resonance (MR), ultrasound, and the 
combination of multimodality imaging has been tried 
to visualize and quantify integrin expression for le-
sion detection and for therapy response monitoring. 
As for therapy applications, integrin antagonists can 
serve  as  antiangiogenic  drugs,  integrin  ligands  can 
also act as delivery vehicles for chemo, radio and gene 
therapeutics. This theme issue consists of 12 reviews 
and was contributed by 28 authors worldwide who 
are among the world’s prominent scientists in molec-
ular imaging and/or molecular pharmaceutics.  
Niu and Chen [1] start with an overall descrip-
tion of the structure, expression pattern, and biologi-
cal/pathological function of various integrins. Beer at 
al. [2] describe different strategies of labeling integrin 
αvβ3 ligands for PET imaging of tumor angiogenesis 
and metastasis in both preclinical models and clinical 
patients. Zhou et al. [3] focus on recent developments 
of integrin αvβ3 targeted radiotracers for SPECT im-
aging of tumors and integrin αIIbβ3 targeted radio-
tracers for SPECT imaging of thrombosis. Approaches 
to maximize targeting capability of cyclic RGD pep-
tides and to improve the radiotracer excretion kinetics 
are also discussed. Ye and Chen [4] summarize fluo-
rescent dyes and quantum dots labeled peptides for 
targeting  integrin  αvβ3  and  several  other  integrin 
subtypes such as α4β1, α3, and β3. Integrin-targeted 
activatable optical probes are also briefly mentioned. 
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ery systems for loading sufficient amount of Gd(III) 
chelates  or  superparamagnetic  nanoparticles  for  T1 
and T2-weighted MR imaging of integrin expression 
in  animal  models.  Kiessling  et  al.  [6]  give  concrete 
examples on the use of molecular ultrasound to char-
acterize integrin expression on blood vessels. Integrin 
targeted microbubbles can be applied in oncology to 
identify and characterize tumor angiogenesis and to 
assess tumor response to antiangiogenic drugs as well 
as to radiotherapy; it can also be a valuable tool for the 
characterization  of  a  broad  spectrum  of  diseases. 
Zhang  et  al.  [7]  argue  that  combination  of  certain 
modalities  can  offer  synergistic  advantages  of  over 
single modality and concentrates on integrin targeting 
contrast agents that can be detected by two or more 
imaging modalities, most of which are based on na-
noparticle  platforms.  Morrison  and  Cuthbertson  [8] 
emphasize the importance of radiolabeled RGD pep-
tides with favorable in vivo kinetics and tumor tar-
geting properties to quantify changes in tumor vas-
cularity  following  anti-cancer  therapies,  particularly 
those that predominantly target tumor blood vessels. 
Millard et al. [9] give rationales on how to design and 
develop potent, selective inhibitors for a number of 
integrins involved in platelet aggregation, inflamma-
tory  responses,  angiongenesis,  neovascularization 
and tumor growth, based on the advances in struc-
tural characterization of integrin-ligand interactions. 
Chen  and  Chen  [10]  summarize  the  bioconjugation 
chemistry  of  coupling  integrin  ligands  and  chemo-
therapeutics to increase the drug load in the tumor 
area while sparing the normal tissue from the expo-
sure to the cytotoxic chemicals. Liu et al.  [11] illus-
trates the potential of beta-emitter labeled antibodies 
and  peptides  for  internal  radiotherapy  of  integrin 
positive tumors. Finally, Juliano et al. [12] review re-
cent  work  concerning  the  targeted  delivery  of  anti-
sense  and  siRNA  oligonuclides  via  integrins  and 
consequently enhance the pharmacological efficacy of 
therapeutic oligonucleotides.  
In summary, it is a very timely collection of lit-
erature reports and provides an overview on the bi-
ology and pathology of various integrins as well as 
in-depth discussion on the use of integrin targeting 
molecules as probes for various imaging modalities: 
PET,  SPECT,  optical  imaging,  MRI  and  ultrasound 
imaging.  In addition, this issue also discusses the use 
of  these  targeting  ligands  to  deliver  radionuclides, 
nanoparticles,  chemotherapeutics  and  therapeutic 
nucleic acids such as antisense and siRNA oligonu-
cleotides to disease sites. 
I thank all the authors for writing this important 
theme  issue,  which  will  undoubtedly  benefit  many 
experts  and  students  in  the  fields  of  cancer 
theranostics. 
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